170 related articles for article (PubMed ID: 9159347)
1. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
Patterson H; Gill S; Fisher C; Law MG; Jayatilake H; Fletcher CD; Thomas M; Grimer R; Gusterson BA; Cooper CS
Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
5. p53 alterations in uterine leiomyosarcomas versus leiomyomas.
de Vos S; Wilczynski SP; Fleischhacker M; Koeffler P
Gynecol Oncol; 1994 Aug; 54(2):205-8. PubMed ID: 8063247
[TBL] [Abstract][Full Text] [Related]
6. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
7. p53 and ras mutations in Ewing's sarcoma.
Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
[TBL] [Abstract][Full Text] [Related]
8. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
9. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
[TBL] [Abstract][Full Text] [Related]
10. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ
Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343
[TBL] [Abstract][Full Text] [Related]
11. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
13. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
14. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
15. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
16. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
17. p53 mutation and absence of mdm2 amplification and Ki-ras mutation in 4-hydroxyamino quinoline 1-oxide induced transplantable osteosarcomas in rats.
Kido A; Tsujiuchi T; Tsutsumi M; Takahama M; Okajima E; Kobitsu K; Miyauchi Y; Mii Y; Tamai S; Konishi Y
Cancer Lett; 1997 Jan; 112(1):5-10. PubMed ID: 9029163
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
20. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
Packenham JP; du Manoir S; Schrock E; Risinger JI; Dixon D; Denz DN; Evans JA; Berchuck A; Barrett JC; Devereux TR; Ried T
Mol Carcinog; 1997 Aug; 19(4):273-9. PubMed ID: 9290705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]